Basimglurant

Multiple biotech companies secured significant funding rounds to advance various innovative treatments and technologies, including autoimmune dysregulation, ADC pipeline, AI-powered natural compounds platform, musculoskeletal disease, kidney disease, NETs, GLP-1 alternatives, insulin delivery system, antibody platform, TGF-beta and protein engineering, bispecific antibody and ADC pipeline, solid tumors, quantum-inspired physics for drug discovery, neuralgia, ALS gene therapy, nicotine inhaler, prostate cancer, protein purification, regenerative osteoarthritis drug, AI-powered cell models, Rett syndrome, GenAI in drug discovery, intracranial hemorrhage, and data storage using molecular technology.

Noema Pharma AG closed a CHF27m Series B extension, totaling CHF130m with EQT Life Sciences. Funds will support four Phase II programs, including basimglurant, gemlapodect, and NOE-115, with key data expected in 2025.

EQT Life Sciences leads a CHF 130 million Series B extension in Noema Pharma, a Basel-based biotech developing CNS disorder treatments. Funds will support late-stage clinical trials for conditions like trigeminal neuralgia and Tourette syndrome, aiming to address unmet medical needs with innovative therapies.

Noema Pharma secures CHF 130M in Series B extension, led by EQT Life Sciences, to advance Phase 2 trials for CNS disorders treatments. Investors include Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, and UPMC Enterprises. Key data readouts expected in 2025.

Noema Pharma secured CHF 130M in Series B extension, led by EQT Life Sciences, to advance Phase 2 trials for CNS disorder treatments. The funding supports trials for basimglurant, gemlapodect, and NOE-115, aiming for 2025 data readouts. EQT joins existing investors, bolstering Noema's clinical programs.